Heparin-Natrium Braun

Heparin‑Natrium Braun is an injectable solution that contains the anticoagulant heparin sodium as its active ingredient. It is supplied in standard concentrations for intravenous or subcutaneous administration and is prescribed in the European Union as a prescription‑only medication. The product works by enhancing antithrombin III activity, thereby inhibiting thrombin and factor Xa to reduce clot formation. It is provided in vials for dosing and is stored under temperature conditions to maintain stability.

Heparin‑Natrium Braun is indicated for several thrombo‑embolic conditions where anticoagulation is required.

- Prevention and treatment of deep vein thrombosis (DVT). - Prevention and treatment of pulmonary embolism (PE). - Prophylaxis of thrombo‑embolic events during major surgery, including orthopedic and cardiac procedures. - Management of acute coronary syndromes, such as unstable angina and myocardial infarction, when rapid anticoagulation is needed. - Use in patients with high risk of clot formation who require short‑term anticoagulant therapy. - Treatment of catheter‑related thrombosis in hemodialysis or infusion lines.

Heparin‑Natrium Braun may cause a range of adverse effects, most of which are related to its anticoagulant activity.

Common: - Minor bleeding or bruising at the injection site. - Small hematomas. - Mild thrombocytopenia. - Nausea or mild gastrointestinal upset.

Serious: - Major hemorrhage (intracranial, gastrointestinal, retroperitoneal). - Heparin‑induced thrombocytopenia with paradoxical clotting. - Severe allergic reactions, including anaphylaxis. - Spinal or epidural hematoma after neuraxial anesthesia.

Before prescribing Heparin‑Natrium Braun, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Assess bleeding risk, including recent surgery, trauma, or active gastrointestinal bleeding. - Review history of heparin‑induced thrombocytopenia or other heparin hypersensitivity. - Monitor platelet counts regularly during therapy to detect HIT. - Adjust dose in patients with renal impairment or extreme body weight. - Avoid use in conjunction with other anticoagulants unless specifically indicated. - Use caution in pregnant or lactating women, as safety data are limited.

Heparin‑Natrium Braun can interact with other medications that affect hemostasis or platelet function.

Avoid: - Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) due to additive bleeding risk. - Combination with antiplatelet agents (e.g., aspirin, clopidogrel) without close monitoring.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) may increase bleeding tendency. - Thrombolytic agents (e.g., alteplase) can potentiate hemorrhage. - Certain antibiotics (e.g., vancomycin) have been reported to enhance HIT risk. - High‑dose corticosteroids may affect platelet function. - Glycoprotein IIb/IIIa inhibitors may increase bleeding risk.